PriceTargets.com logo

NASDAQ:XFOR - X4 Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 278.79 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$5.28 As of 09/17/2021 01:00 AM ET
▲ +0.3 (6.02%)

This chart shows the closing price for XFOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New X4 Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XFOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XFOR

Analyst Price Target is $20.00
▲ +278.79% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for X4 Pharmaceuticals in the last 3 months. The average price target is $20.00, with a high forecast of $27.00 and a low forecast of $15.00. The average price target represents a 278.79% upside from the last price of $5.28.

This chart shows the closing price for XFOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in X4 Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/14/2021HC WainwrightReiterated RatingBuy$21.00Medium
6/11/2021Roth CapitalReiterated RatingPositive ➝ Buy$23.00 ➝ $27.00Low
3/22/2021OppenheimerReiterated RatingBuy$16.00High
12/17/2020Brookline Capital ManagementInitiated CoverageBuy$21.00High
11/30/2020B. RileyReiterated RatingBuy$15.00Medium
11/9/2020Canaccord GenuityLower Price TargetBuy$22.00 ➝ $20.00High
6/12/2020B. RileyReiterated RatingBuy$15.00Medium
5/26/2020Canaccord GenuityReiterated RatingBuyHigh
5/8/2020B. RileyLower Price TargetBuy$19.00 ➝ $15.00Medium
5/8/2020HC WainwrightLower Price TargetOutperform$22.00 ➝ $21.00Medium
5/7/2020OppenheimerReiterated RatingBuy$20.00Medium
4/12/2020HC WainwrightReiterated RatingBuy$22.00High
3/26/2020CitigroupLower Price TargetBuy$16.00 ➝ $15.00High
3/13/2020B. RileyLower Price TargetBuy$25.00 ➝ $19.00Medium
3/12/2020CowenReiterated RatingBuyMedium
2/13/2020Roth CapitalReiterated RatingBuyMedium
1/7/2020HC WainwrightInitiated CoverageBuy$22.00Low
12/23/2019OppenheimerInitiated CoverageOutperform$20.00High
12/18/2019Roth CapitalInitiated CoverageBuy$20.00Medium
12/9/2019CitigroupUpgradeNeutral ➝ Buy$16.00 ➝ $20.00Medium
12/5/2019B. RileyInitiated CoverageBuy$25.00High
10/10/2019CowenReiterated RatingBuyLow
9/30/2019CowenReiterated RatingBuyLow
6/7/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$27.00High
6/5/2019CowenInitiated CoverageOutperform ➝ OutperformLow
5/21/2019Canaccord GenuityInitiated CoverageBuy$27.00Medium
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2021

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

X4 Pharmaceuticals logo
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Boston, MA.
Read More

Today's Range

Now: $5.28
Low: $4.80
High: $5.38

50 Day Range

MA: $5.42
Low: $4.53
High: $6.44

52 Week Range

Now: $5.28
Low: $4.25
High: $10.70

Volume

199,936 shs

Average Volume

149,866 shs

Market Capitalization

$131.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54

Frequently Asked Questions

What sell-side analysts currently cover shares of X4 Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on X4 Pharmaceuticals in the last twelve months: B. Riley, Brookline Capital Management, Canaccord Genuity, HC Wainwright, Oppenheimer Holdings Inc., Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for XFOR.

What is the current price target for X4 Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for X4 Pharmaceuticals in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 278.8%. Roth Capital has the highest price target set, predicting XFOR will reach $27.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $15.00 for X4 Pharmaceuticals in the next year.
View the latest price targets for XFOR.

What is the current consensus analyst rating for X4 Pharmaceuticals?

X4 Pharmaceuticals currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XFOR will outperform the market and that investors should add to their positions of X4 Pharmaceuticals.
View the latest ratings for XFOR.

What other companies compete with X4 Pharmaceuticals?

Other companies that are similar to X4 Pharmaceuticals include CEL-SCI, Poseida Therapeutics, Autolus Therapeutics, Tarsus Pharmaceuticals, Ikena Oncology, Compugen, Innate Pharma, Codiak BioSciences, Lineage Cell Therapeutics, SQZ Biotechnologies, Outlook Therapeutics, Jounce Therapeutics, Fusion Pharmaceuticals, Athira Pharma and Orchard Therapeutics.

How do I contact X4 Pharmaceuticals' investor relations team?

X4 Pharmaceuticals' physical mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company's listed phone number is (857) 529-8300 and its investor relations email address is [email protected] The official website for X4 Pharmaceuticals is www.x4pharma.com.